Share Price and Basic Stock Data
Last Updated: November 3, 2025, 9:56 pm
| PEG Ratio | -1.71 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Sanofi India Ltd operates in the pharmaceuticals sector, focusing on the development, manufacturing, and marketing of a wide range of healthcare products. The company’s revenue reported for the trailing twelve months (TTM) stood at ₹1,981 Cr, which reflects a notable decline from ₹2,770 Cr in the fiscal year ending December 2022. Quarterly sales have shown a downward trend, with the latest figure for September 2023 at ₹491 Cr, down from ₹515 Cr in June 2023. This declining revenue trajectory raises concerns, particularly as the industry typically experiences stable growth. The operating profit margin (OPM) for the most recent quarter was recorded at 23%, which is in line with industry standards, but the overall sales drop could impact future growth prospects. The company reported net profits of ₹362 Cr, which is a decrease from previous years, demonstrating the challenges faced in maintaining revenue stability amidst competitive pressures. Sanofi India’s ability to innovate and respond to market needs will be crucial in reversing this trend.
Profitability and Efficiency Metrics
Sanofi India Ltd reported a net profit of ₹362 Cr, which translates to an earnings per share (EPS) of ₹157.62 for the TTM. The company’s return on equity (ROE) stood at an impressive 47.2%, indicating efficient utilization of shareholder funds. However, the operating profit for the latest quarter was ₹114 Cr, showcasing a decline from ₹122 Cr in June 2023, which may signal operational inefficiencies. The interest coverage ratio (ICR) was exceptionally high at 338.20x, indicating that the company generates ample earnings to cover its interest obligations. The cash conversion cycle (CCC) was reported at 77 days, suggesting a moderate efficiency in managing receivables, payables, and inventory levels. While profitability metrics remain robust, the declining operating profit raises questions about cost management and pricing strategies in an increasingly competitive market. Overall, Sanofi India must focus on enhancing operational efficiency to sustain its profitability amidst these challenges.
Balance Sheet Strength and Financial Ratios
Sanofi India Ltd’s balance sheet reflects a strong financial position, with total assets amounting to ₹1,239 Cr and total liabilities standing at ₹1,612 Cr. The company’s reserves have decreased to ₹759 Cr, down from ₹1,253 Cr in December 2022, which could impact its ability to invest in growth opportunities. Borrowings remained low at ₹21 Cr, indicating minimal reliance on debt financing, which enhances financial stability. The price-to-book value (P/BV) ratio was reported at 16.36x, significantly higher than the typical sector range, which suggests that the stock may be overvalued relative to its book value. The current ratio stood at 1.57x, indicating that the company maintains sufficient liquidity to cover short-term obligations. However, the declining reserves and high P/BV ratio are areas of concern that investors should closely monitor, as they could affect the company’s long-term financial health and ability to navigate market fluctuations.
Shareholding Pattern and Investor Confidence
As of June 2025, promoters hold a substantial 60.40% stake in Sanofi India Ltd, indicating strong control over the company’s strategic direction. Foreign institutional investors (FIIs) accounted for 5.61%, reflecting a slight decrease from previous quarters, while domestic institutional investors (DIIs) held 23.06%, demonstrating a stable interest from local institutions. The public shareholding stood at 10.94%, which is relatively low and may limit market liquidity. The total number of shareholders decreased to 66,790, a decline from previous periods, suggesting potential investor concerns about the company’s recent performance. The consistent promoter holding coupled with a significant institutional presence can be seen as a vote of confidence; however, the declining public interest could pose risks in terms of market perception and stock liquidity. Maintaining investor confidence will be critical as the company navigates through operational challenges and strives for growth.
Outlook, Risks, and Final Insight
Looking ahead, Sanofi India Ltd faces both opportunities and challenges. The company’s strong ROE and ICR position it well for potential recovery, but it must address the declining revenue trends and profitability metrics to regain investor confidence. Key risks include operational inefficiencies and a potential decline in market share due to increased competition in the pharmaceuticals sector. Additionally, the high P/BV ratio may indicate overvaluation, which could deter new investments if performance does not improve. Strategies focusing on innovation, cost management, and market expansion will be vital for reversing the current trends. If Sanofi India can effectively leverage its strong financial metrics while addressing operational challenges, it could enhance its market position significantly. Conversely, failure to adapt could lead to further declines in performance and investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Sanofi India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 247/84.3 | 33.0 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,079 Cr. | 464 | 479/192 | 114 | 22.8 | 0.14 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 35.1 Cr. | 24.0 | 29.1/17.0 | 36.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,966.35 Cr | 1,197.73 | 54.46 | 195.30 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 699 | 692 | 672 | 736 | 515 | 491 | 469 | 511 | 464 | 524 | 515 | 536 | 406 |
| Expenses | 538 | 510 | 505 | 507 | 393 | 377 | 370 | 374 | 348 | 404 | 397 | 364 | 311 |
| Operating Profit | 161 | 182 | 167 | 230 | 122 | 114 | 100 | 137 | 116 | 120 | 118 | 172 | 95 |
| OPM % | 23% | 26% | 25% | 31% | 24% | 23% | 21% | 27% | 25% | 23% | 23% | 32% | 23% |
| Other Income | 16 | 11 | 34 | 44 | 57 | 82 | 77 | 41 | 21 | 2 | 14 | 3 | 9 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 11 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 9 |
| Profit before tax | 166 | 182 | 190 | 264 | 169 | 186 | 167 | 169 | 127 | 113 | 122 | 165 | 94 |
| Tax % | 27% | 28% | 31% | 28% | 27% | 18% | 18% | 19% | 19% | 27% | 25% | 28% | 26% |
| Net Profit | 120 | 131 | 131 | 190 | 123 | 152 | 138 | 137 | 103 | 82 | 91 | 120 | 70 |
| EPS in Rs | 52.35 | 56.91 | 56.91 | 82.78 | 53.43 | 66.17 | 59.87 | 59.39 | 44.96 | 35.74 | 39.70 | 51.96 | 30.22 |
Last Updated: August 1, 2025, 12:30 pm
Below is a detailed analysis of the quarterly data for Sanofi India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 406.00 Cr.. The value appears to be declining and may need further review. It has decreased from 536.00 Cr. (Mar 2025) to 406.00 Cr., marking a decrease of 130.00 Cr..
- For Expenses, as of Jun 2025, the value is 311.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 364.00 Cr. (Mar 2025) to 311.00 Cr., marking a decrease of 53.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 95.00 Cr.. The value appears to be declining and may need further review. It has decreased from 172.00 Cr. (Mar 2025) to 95.00 Cr., marking a decrease of 77.00 Cr..
- For OPM %, as of Jun 2025, the value is 23.00%. The value appears to be declining and may need further review. It has decreased from 32.00% (Mar 2025) to 23.00%, marking a decrease of 9.00%.
- For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 6.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.00 Cr. (Mar 2025) to 9.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 94.00 Cr.. The value appears to be declining and may need further review. It has decreased from 165.00 Cr. (Mar 2025) to 94.00 Cr., marking a decrease of 71.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Mar 2025) to 26.00%, marking a decrease of 2.00%.
- For Net Profit, as of Jun 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 50.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 30.22. The value appears to be declining and may need further review. It has decreased from 51.96 (Mar 2025) to 30.22, marking a decrease of 21.74.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 2:08 pm
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,809 | 1,977 | 2,193 | 2,367 | 2,460 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 1,996 | 2,013 | 1,981 |
| Expenses | 1,411 | 1,639 | 1,817 | 1,832 | 1,921 | 2,146 | 2,403 | 2,186 | 2,194 | 2,066 | 1,508 | 1,522 | 1,476 |
| Operating Profit | 398 | 339 | 376 | 535 | 538 | 625 | 667 | 716 | 762 | 704 | 488 | 491 | 505 |
| OPM % | 22% | 17% | 17% | 23% | 22% | 23% | 22% | 25% | 26% | 25% | 24% | 24% | 25% |
| Other Income | 83 | 131 | 218 | 66 | 79 | 88 | 33 | 45 | 564 | 204 | 318 | 79 | 28 |
| Interest | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 92 | 97 | 113 | 119 | 102 | 103 | 100 | 82 | 67 | 42 | 36 | 37 | 37 |
| Profit before tax | 388 | 373 | 481 | 480 | 515 | 610 | 600 | 677 | 1,258 | 864 | 767 | 531 | 494 |
| Tax % | 32% | 29% | 33% | 37% | 37% | 38% | 31% | 29% | 25% | 28% | 21% | 22% | |
| Net Profit | 265 | 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 621 | 603 | 414 | 362 |
| EPS in Rs | 115.30 | 114.61 | 139.78 | 132.26 | 141.74 | 165.48 | 180.09 | 207.65 | 410.61 | 269.83 | 262.26 | 179.78 | 157.62 |
| Dividend Payout % | 39% | 39% | 46% | 51% | 50% | 51% | 194% | 176% | 119% | 211% | 64% | 65% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -8% |
| 3 Years: | -12% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 0% |
| 3 Years: | -9% |
| TTM: | 1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 0% |
| 3 Years: | 11% |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 32% |
| 3 Years: | 41% |
| Last Year: | 47% |
Last Updated: September 5, 2025, 1:25 pm
Balance Sheet
Last Updated: August 11, 2025, 2:43 pm
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
| Reserves | 1,324 | 1,463 | 1,604 | 1,860 | 2,003 | 2,196 | 2,419 | 2,096 | 2,203 | 1,253 | 992 | 838 | 759 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 25 | 24 | 19 | 19 | 21 |
| Other Liabilities | 532 | 742 | 778 | 658 | 751 | 765 | 802 | 777 | 811 | 772 | 681 | 732 | 436 |
| Total Liabilities | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,239 |
| Fixed Assets | 699 | 648 | 877 | 817 | 769 | 733 | 499 | 464 | 334 | 306 | 315 | 312 | 309 |
| CWIP | 136 | 210 | 22 | 34 | 30 | 21 | 17 | 10 | 13 | 24 | 16 | 18 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Other Assets | 1,043 | 1,369 | 1,505 | 1,690 | 1,978 | 2,230 | 2,728 | 2,444 | 2,714 | 1,743 | 1,382 | 1,281 | 914 |
| Total Assets | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,239 |
Below is a detailed analysis of the balance sheet data for Sanofi India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Equity Capital, as of Jun 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 23.00 Cr..
- For Reserves, as of Jun 2025, the value is 759.00 Cr.. The value appears to be declining and may need further review. It has decreased from 838.00 Cr. (Dec 2024) to 759.00 Cr., marking a decrease of 79.00 Cr..
- For Borrowings, as of Jun 2025, the value is 21.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 19.00 Cr. (Dec 2024) to 21.00 Cr., marking an increase of 2.00 Cr..
- For Other Liabilities, as of Jun 2025, the value is 436.00 Cr.. The value appears to be improving (decreasing). It has decreased from 732.00 Cr. (Dec 2024) to 436.00 Cr., marking a decrease of 296.00 Cr..
- For Total Liabilities, as of Jun 2025, the value is 1,239.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,612.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 373.00 Cr..
- For Fixed Assets, as of Jun 2025, the value is 309.00 Cr.. The value appears to be declining and may need further review. It has decreased from 312.00 Cr. (Dec 2024) to 309.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Dec 2024) to 16.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Other Assets, as of Jun 2025, the value is 914.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,281.00 Cr. (Dec 2024) to 914.00 Cr., marking a decrease of 367.00 Cr..
- For Total Assets, as of Jun 2025, the value is 1,239.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,612.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 373.00 Cr..
Notably, the Reserves (759.00 Cr.) exceed the Borrowings (21.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 398.00 | 339.00 | 376.00 | 535.00 | 538.00 | 625.00 | 667.00 | 693.00 | 737.00 | 680.00 | 469.00 | 472.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 24 | 21 | 24 | 22 | 29 | 21 | 27 | 19 | 18 | 17 | 24 | 42 |
| Inventory Days | 151 | 179 | 173 | 169 | 151 | 154 | 127 | 107 | 110 | 125 | 254 | 186 |
| Days Payable | 83 | 122 | 81 | 79 | 119 | 110 | 100 | 93 | 105 | 109 | 112 | 151 |
| Cash Conversion Cycle | 92 | 78 | 115 | 112 | 61 | 65 | 54 | 33 | 22 | 33 | 167 | 77 |
| Working Capital Days | 43 | 26 | 9 | 79 | 17 | 18 | 35 | -8 | -20 | -19 | 35 | 20 |
| ROCE % | 29% | 22% | 26% | 27% | 26% | 29% | 28% | 32% | 35% | 41% | 44% | 49% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Frontline Equity Fund | 268,508 | 0.84 | 216.62 | 268,508 | 2025-04-22 17:25:21 | 0% |
| Nippon India Pharma Fund | 236,008 | 2.94 | 190.4 | 236,008 | 2025-04-22 17:25:21 | 0% |
| Nippon India Growth Fund | 226,766 | 0.78 | 182.94 | 226,766 | 2025-04-22 17:25:21 | 0% |
| Nippon India Small Cap Fund | 196,342 | 0.36 | 158.4 | 196,342 | 2025-04-22 17:25:21 | 0% |
| SBI Contra Fund | 161,000 | 0.68 | 129.5 | 161,000 | 2025-04-22 17:25:21 | 0% |
| Nippon India Multi Cap Fund | 152,371 | 0.5 | 122.93 | 152,371 | 2025-04-22 17:25:21 | 0% |
| SBI Long Term Equity Fund | 147,988 | 0.69 | 119.04 | 147,988 | 2025-04-22 17:25:21 | 0% |
| Aditya Birla Sun Life Small Cap Fund | 144,433 | 2.22 | 116.52 | 144,433 | 2025-04-22 17:25:21 | 0% |
| SBI Magnum Midcap Fund | 100,837 | 0.56 | 81.11 | 100,837 | 2025-04-22 17:25:21 | 0% |
| Aditya Birla Sun Life Multi-Cap Fund | 87,342 | 1.43 | 70.46 | 87,342 | 2025-04-22 17:25:21 | 0% |
Key Financial Ratios
| Month | Dec 24 | Dec 23 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 179.46 | 261.78 |
| Diluted EPS (Rs.) | 179.46 | 261.78 |
| Cash EPS (Rs.) | 195.65 | 279.35 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 374.17 | 441.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 374.17 | 441.39 |
| Revenue From Operations / Share (Rs.) | 875.30 | 1239.61 |
| PBDIT / Share (Rs.) | 220.57 | 377.83 |
| PBIT / Share (Rs.) | 204.61 | 360.61 |
| PBT / Share (Rs.) | 187.57 | 367.61 |
| Net Profit / Share (Rs.) | 179.69 | 262.13 |
| NP After MI And SOA / Share (Rs.) | 179.69 | 262.13 |
| PBDIT Margin (%) | 25.19 | 30.47 |
| PBIT Margin (%) | 23.37 | 29.09 |
| PBT Margin (%) | 21.42 | 29.65 |
| Net Profit Margin (%) | 20.52 | 21.14 |
| NP After MI And SOA Margin (%) | 20.52 | 21.14 |
| Return on Networth / Equity (%) | 48.02 | 59.38 |
| Return on Capital Employeed (%) | 52.72 | 77.98 |
| Return On Assets (%) | 25.64 | 35.15 |
| Asset Turnover Ratio (%) | 1.21 | 0.00 |
| Current Ratio (X) | 1.57 | 1.92 |
| Quick Ratio (X) | 0.87 | 0.89 |
| Inventory Turnover Ratio (X) | 0.60 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 139.85 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 131.23 |
| Earning Retention Ratio (%) | 0.00 | -39.85 |
| Cash Earning Retention Ratio (%) | 0.00 | -31.23 |
| Interest Coverage Ratio (X) | 338.20 | 511.18 |
| Interest Coverage Ratio (Post Tax) (X) | 235.27 | 345.18 |
| Enterprise Value (Cr.) | 13783.39 | 18147.83 |
| EV / Net Operating Revenue (X) | 6.85 | 6.37 |
| EV / EBITDA (X) | 27.17 | 20.88 |
| MarketCap / Net Operating Revenue (X) | 6.99 | 6.51 |
| Retention Ratios (%) | 0.00 | -39.85 |
| Price / BV (X) | 16.36 | 18.28 |
| Price / Net Operating Revenue (X) | 6.99 | 6.51 |
| EarningsYield | 0.02 | 0.03 |
After reviewing the key financial ratios for Sanofi India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Dec 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Dec 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
- For Diluted EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
- For Cash EPS (Rs.), as of Dec 24, the value is 195.65. This value is within the healthy range. It has decreased from 279.35 (Dec 23) to 195.65, marking a decrease of 83.70.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
- For Revenue From Operations / Share (Rs.), as of Dec 24, the value is 875.30. It has decreased from 1,239.61 (Dec 23) to 875.30, marking a decrease of 364.31.
- For PBDIT / Share (Rs.), as of Dec 24, the value is 220.57. This value is within the healthy range. It has decreased from 377.83 (Dec 23) to 220.57, marking a decrease of 157.26.
- For PBIT / Share (Rs.), as of Dec 24, the value is 204.61. This value is within the healthy range. It has decreased from 360.61 (Dec 23) to 204.61, marking a decrease of 156.00.
- For PBT / Share (Rs.), as of Dec 24, the value is 187.57. This value is within the healthy range. It has decreased from 367.61 (Dec 23) to 187.57, marking a decrease of 180.04.
- For Net Profit / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
- For NP After MI And SOA / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
- For PBDIT Margin (%), as of Dec 24, the value is 25.19. This value is within the healthy range. It has decreased from 30.47 (Dec 23) to 25.19, marking a decrease of 5.28.
- For PBIT Margin (%), as of Dec 24, the value is 23.37. This value exceeds the healthy maximum of 20. It has decreased from 29.09 (Dec 23) to 23.37, marking a decrease of 5.72.
- For PBT Margin (%), as of Dec 24, the value is 21.42. This value is within the healthy range. It has decreased from 29.65 (Dec 23) to 21.42, marking a decrease of 8.23.
- For Net Profit Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 10. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 20. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
- For Return on Networth / Equity (%), as of Dec 24, the value is 48.02. This value is within the healthy range. It has decreased from 59.38 (Dec 23) to 48.02, marking a decrease of 11.36.
- For Return on Capital Employeed (%), as of Dec 24, the value is 52.72. This value is within the healthy range. It has decreased from 77.98 (Dec 23) to 52.72, marking a decrease of 25.26.
- For Return On Assets (%), as of Dec 24, the value is 25.64. This value is within the healthy range. It has decreased from 35.15 (Dec 23) to 25.64, marking a decrease of 9.51.
- For Asset Turnover Ratio (%), as of Dec 24, the value is 1.21. It has increased from 0.00 (Dec 23) to 1.21, marking an increase of 1.21.
- For Current Ratio (X), as of Dec 24, the value is 1.57. This value is within the healthy range. It has decreased from 1.92 (Dec 23) to 1.57, marking a decrease of 0.35.
- For Quick Ratio (X), as of Dec 24, the value is 0.87. This value is below the healthy minimum of 1. It has decreased from 0.89 (Dec 23) to 0.87, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Dec 24, the value is 0.60. This value is below the healthy minimum of 4. It has increased from 0.00 (Dec 23) to 0.60, marking an increase of 0.60.
- For Dividend Payout Ratio (NP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 139.85 (Dec 23) to 0.00, marking a decrease of 139.85.
- For Dividend Payout Ratio (CP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 131.23 (Dec 23) to 0.00, marking a decrease of 131.23.
- For Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
- For Cash Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -31.23 (Dec 23) to 0.00, marking an increase of 31.23.
- For Interest Coverage Ratio (X), as of Dec 24, the value is 338.20. This value is within the healthy range. It has decreased from 511.18 (Dec 23) to 338.20, marking a decrease of 172.98.
- For Interest Coverage Ratio (Post Tax) (X), as of Dec 24, the value is 235.27. This value is within the healthy range. It has decreased from 345.18 (Dec 23) to 235.27, marking a decrease of 109.91.
- For Enterprise Value (Cr.), as of Dec 24, the value is 13,783.39. It has decreased from 18,147.83 (Dec 23) to 13,783.39, marking a decrease of 4,364.44.
- For EV / Net Operating Revenue (X), as of Dec 24, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 6.37 (Dec 23) to 6.85, marking an increase of 0.48.
- For EV / EBITDA (X), as of Dec 24, the value is 27.17. This value exceeds the healthy maximum of 15. It has increased from 20.88 (Dec 23) to 27.17, marking an increase of 6.29.
- For MarketCap / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
- For Retention Ratios (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 30. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
- For Price / BV (X), as of Dec 24, the value is 16.36. This value exceeds the healthy maximum of 3. It has decreased from 18.28 (Dec 23) to 16.36, marking a decrease of 1.92.
- For Price / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
- For EarningsYield, as of Dec 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Dec 23) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sanofi India Ltd:
- Net Profit Margin: 20.52%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 52.72% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 48.02% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 235.27
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.87
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 29.8 (Industry average Stock P/E: 54.46)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 20.52%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Sanofi House, Mumbai Maharashtra 400072 | igrc.sil@sanofi.com http://www.sanofiindialtd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aditya Narayan | Chairman & Ind.Director |
| Mr. Rodolfo Hrosz | Managing Director |
| Mr. Rachid Ayari | WholeTime Director & CFO |
| Ms. Renee Amonkar | Whole Time Director |
| Mr. Vaibhav Karandikar | Non Executive Director |
| Mrs. Usha Thorat | Independent Director |
| Mr. Rahul Bhatnagar | Independent Director |
FAQ
What is the intrinsic value of Sanofi India Ltd?
Sanofi India Ltd's intrinsic value (as of 03 November 2025) is 3919.58 which is 18.05% lower the current market price of 4,783.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 11,016 Cr. market cap, FY2025-2026 high/low of 6,823/4,146, reserves of ₹759 Cr, and liabilities of 1,239 Cr.
What is the Market Cap of Sanofi India Ltd?
The Market Cap of Sanofi India Ltd is 11,016 Cr..
What is the current Stock Price of Sanofi India Ltd as on 03 November 2025?
The current stock price of Sanofi India Ltd as on 03 November 2025 is 4,783.
What is the High / Low of Sanofi India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sanofi India Ltd stocks is 6,823/4,146.
What is the Stock P/E of Sanofi India Ltd?
The Stock P/E of Sanofi India Ltd is 29.8.
What is the Book Value of Sanofi India Ltd?
The Book Value of Sanofi India Ltd is 340.
What is the Dividend Yield of Sanofi India Ltd?
The Dividend Yield of Sanofi India Ltd is 2.45 %.
What is the ROCE of Sanofi India Ltd?
The ROCE of Sanofi India Ltd is 49.2 %.
What is the ROE of Sanofi India Ltd?
The ROE of Sanofi India Ltd is 47.2 %.
What is the Face Value of Sanofi India Ltd?
The Face Value of Sanofi India Ltd is 10.0.